医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2014年
25期
233-234
,共2页
熊去氧胆酸%药物性肝损%治疗
熊去氧膽痠%藥物性肝損%治療
웅거양담산%약물성간손%치료
UDCA%DILI%treatment
目的：分析熊去氧胆酸（优思弗）治疗药物性肝损伤的临床疗效及其安全性。方法：回顾性汇总分析60例临床诊断药物性肝损的住院患者，按是否应用优思弗将患者分为两组：优思弗组(30例)和对照组(30例)，统计分析两组患者治疗前后的临床特征、各项生化等指标并进行统计学分析。结果：两组患者治疗前肝功能无显著差异。二组在治疗前后ALT、AST、TBil对比均存在差异，两组间治疗后肝功能比较，ALT、AST、TBil存在差异。在胆汁淤积型和混合型患者中治疗前后的TBil、GGT、ALP存在统计学差异。而在肝细胞损伤型患者中治疗前后ALT、AST存在统计学差异。优思弗组治疗后16例患者显效，12例患者有效，2例无效，总有效率93.3%，对照组8例显效，12例有效，10例无效，总有效率66.7%，两组疗效对比有明显的统计学差异。结论：熊去氧胆酸可以改善各型药物性肝损的临床症状和肝功能指标，且其不良反应少，是目前治疗药物性肝损的重要选择。
目的：分析熊去氧膽痠（優思弗）治療藥物性肝損傷的臨床療效及其安全性。方法：迴顧性彙總分析60例臨床診斷藥物性肝損的住院患者，按是否應用優思弗將患者分為兩組：優思弗組(30例)和對照組(30例)，統計分析兩組患者治療前後的臨床特徵、各項生化等指標併進行統計學分析。結果：兩組患者治療前肝功能無顯著差異。二組在治療前後ALT、AST、TBil對比均存在差異，兩組間治療後肝功能比較，ALT、AST、TBil存在差異。在膽汁淤積型和混閤型患者中治療前後的TBil、GGT、ALP存在統計學差異。而在肝細胞損傷型患者中治療前後ALT、AST存在統計學差異。優思弗組治療後16例患者顯效，12例患者有效，2例無效，總有效率93.3%，對照組8例顯效，12例有效，10例無效，總有效率66.7%，兩組療效對比有明顯的統計學差異。結論：熊去氧膽痠可以改善各型藥物性肝損的臨床癥狀和肝功能指標，且其不良反應少，是目前治療藥物性肝損的重要選擇。
목적：분석웅거양담산（우사불）치료약물성간손상적림상료효급기안전성。방법：회고성회총분석60례림상진단약물성간손적주원환자，안시부응용우사불장환자분위량조：우사불조(30례)화대조조(30례)，통계분석량조환자치료전후적림상특정、각항생화등지표병진행통계학분석。결과：량조환자치료전간공능무현저차이。이조재치료전후ALT、AST、TBil대비균존재차이，량조간치료후간공능비교，ALT、AST、TBil존재차이。재담즙어적형화혼합형환자중치료전후적TBil、GGT、ALP존재통계학차이。이재간세포손상형환자중치료전후ALT、AST존재통계학차이。우사불조치료후16례환자현효，12례환자유효，2례무효，총유효솔93.3%，대조조8례현효，12례유효，10례무효，총유효솔66.7%，량조료효대비유명현적통계학차이。결론：웅거양담산가이개선각형약물성간손적림상증상화간공능지표，차기불량반응소，시목전치료약물성간손적중요선택。
Objective To explore the curative effect and safety of ursodeoxycholic acid(UDCA) in treating drug-inducedliverinjury(DILI).Method Sixty cases of DILI patients in hospital were retrospectively analyizedm. Al cases were divided into the control group (30 cases) and the observation group(30 cases).The observation group was given UDCA additional y. The score of clinical feature and biochemistry index were compared between the two groups. Results There were no significant difference in the liver function between two group patients before treatment, The ALT、AST、TBil level of two groups were Statistical differences than that of the groups before treatment .The TBil level of patients with Cholestasis and patients with mixed type after treatment were Statistical differences than that of the patients before treatment . The ALT\AST level of patients with hepatocel uar injury after treatment were statistical differences than that of the patients before treatment . Clinical analysis, In the treatment group, 16 cases were significantly improved, 12 cases were improved and 2 cases were invalid. The total effective rate was 93 %. When come to control group, the dates were 8,2,10 respectively , and the total effective rate was 63 %. There exist ‐ ed significant difference in t therapeutic effect between the two groups Conclusion UDCA can obviously improved the clinical symptoms and liver function of the DILI patients,and fewer side effects,UDCA is currently the fundamental choice with therapy for chronic myeloid leukemia.
